# Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

> **NCT03722186** · PHASE1 · SUSPENDED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Physiological Effects of Drugs
- Neoplasms by Histologic Type
- Lymphoma
- Hematologic Neoplasms
- Immunotherapy
- Advanced Cancer

## Interventions

- **DRUG:** SHR-1603

## Key facts

- **NCT ID:** NCT03722186
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-11-13
- **Primary completion:** 2019-04-04
- **Final completion:** 2021-10
- **Target enrollment:** 128 (ESTIMATED)
- **Why stopped:** Business Decision
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722186, "Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03722186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*